Related Experiment Videos
Fulminant hepatic failure associated with etodolac use
C L Mabee1, S W Mabee, P B Baker
1Department of Gastroenterology, Ohio State University Medical Center, Columbus, USA.
The American Journal of Gastroenterology
|April 1, 1995
Abstract:
Etodolac is a new pyranocarboxylic acid nonsteroidal anti-inflammatory agent with a unique chemical structure indicated for use in patients with painful musculoskeletal disorders and rheumatoid disease. Hepatotoxicity, in the form of reversible elevations in transaminases or bilirubin, occurs rarely. We present the first reported case of fulminant hepatic failure related to etodolac.